We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




AI Tool Rapidly Analyzes Gene Activities in Medical Images to Highlight Hidden Cancers

By LabMedica International staff writers
Posted on 03 Jan 2024
Print article
Image: A new AI tool brings precision pathology for cancer and beyond into quicker, sharper focus (Photo courtesy of 123RF)
Image: A new AI tool brings precision pathology for cancer and beyond into quicker, sharper focus (Photo courtesy of 123RF)

A novel artificial intelligence (AI) tool, designed to interpret medical images with exceptional clarity, is set to revolutionize the way clinicians approach disease diagnosis and image analysis.

This advanced tool, named iStar (Inferring Super-Resolution Tissue Architecture), was developed by researchers at the Perelman School of Medicine at the University of Pennsylvania (Philadelphia, PA, USA). It can assist healthcare professionals in diagnosing and treating cancers that might otherwise remain undetected. iStar offers an in-depth view of individual cells and a broader look at the full range of human gene activity, potentially revealing cancer cells that were nearly invisible earlier. This tool could play a crucial role in confirming whether cancer surgeries have fully removed malignancies and provide automatic annotations for microscopic images, marking a significant leap toward molecular-level disease diagnosis. One of the standout capabilities of iStar is its automatic identification of crucial anti-tumor immune formations known as "tertiary lymphoid structures," which are indicators of a patient's survival prospects and their likely response to immunotherapy. This precision makes iStar a powerful tool for selecting the right patients for immunotherapy treatments.

The researchers put iStar to the test across various cancer types, including breast, prostate, kidney, and colorectal cancers, alongside healthy tissue samples. In these trials, iStar automatically detected tumor and cancer cells that were challenging to spot with the naked eye. With iStar as an additional support layer, clinicians might soon be able to diagnose more elusive cancers effectively. Moreover, iStar operates at a remarkably fast pace compared to similar AI tools. In a trial with a breast cancer dataset, iStar completed its analysis in a mere nine minutes, whereas the closest competing AI tool took over 32 hours to deliver a comparable analysis. This makes iStar an astounding 213 times faster, offering a significant advantage in time-sensitive clinical environments.

“The power of iStar stems from its advanced techniques, which mirror, in reverse, how a pathologist would study a tissue sample,” explained Mingyao Li, Ph.D., a professor of Biostatistics and Digital Pathology. “Just as a pathologist identifies broader regions and then zooms in on detailed cellular structures, iStar can capture the overarching tissue structures and also focus on the minutiae in a tissue image.”

Related Links:
Perelman School of Medicine

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Dengue Virus Test
LINEAR Dengue-CHIK

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Molecular Diagnostics

view channel
Image: Researchers have found the first evidence of testing for the alpha-synuclein protein in blood samples via seed amplification assay (Photo courtesy of Shutterstock)

Blood Test to Detect Alpha-Synuclein Protein Could Revolutionize Parkinson's Disease Diagnostics

Currently, Parkinson's disease (PD) is identified through clinical diagnosis, typically at a later stage in the disease's progression. There is a pressing need for an objective and quantifiable biomarker... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: Ultra-Rapid Antimicrobial Susceptibility Testing (uRAST) revolutionizing traditional antibiotic susceptibility testing (Photo courtesy of Seoul National University)

Ultra-Rapid Culture-Free Sepsis Test Reduces Testing Time from Days to Hours

Sepsis, a critical emergency condition, results from an overactive inflammatory response to pathogens like bacteria or fungi in the blood, leading to organ damage and the possibility of sudden death.... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.